-transparent.png){kind=logo}
Triggering of the CD3 molecule by in vivo injection of the hamster anti-murine CD3 monoclonal antibody 145-2C11 in adult BALB/c mice leads to massive although transient T cell activation. High levels of tumour necrosis factor (TNF), interferon-gamma (IFN-gamma), IL-2, IL-3 and IL-6 are released into the circulation 1 to 8 h after a single 10 micrograms 145-2C11 i.v. injection. This release induces an impressive self-limited physical reaction associating hypothermia, hypomotility (as assessed by actimetry), diarrhoea, piloerection and even death when high doses (a single dose of greater than 100 micrograms/mouse injection) are administered. In vivo injection of 145-2C11 to other selected mouse strains, namely NZW, CBA/J and C3H/HeJ, induced both different cytokine release patterns and sickness. 145-2C11 induced significant release of TNF and IL-2 in all four strains. At variance, IFN-gamma was only detected in BALB/c mice sera which, in terms of physical reaction (hypothermia and hypomotility) were the most affected. Higher and long-lasting circulating IL-3/GM-CSF levels were present in CBA/J sera, correlating with a later recovery. These results underline heterogeneity in the in vivo cell activation pattern among different mouse strains, when triggering T lymphocytes via the CD3/Ti molecule as compared to exclusive targeting of monocyte/macrophages by means of lipopolysaccharide.
C Ferran, and
M Dy, and
K Sheehan, and
S Merite, and
R Schreiber, and
P Landais, and
G Grau, and
J Bluestone, and
J F Bach, and
L Chatenoud
October 1991,
Transplantation,
C Ferran, and
M Dy, and
K Sheehan, and
S Merite, and
R Schreiber, and
P Landais, and
G Grau, and
J Bluestone, and
J F Bach, and
L Chatenoud
August 2021,
European journal of immunology,
C Ferran, and
M Dy, and
K Sheehan, and
S Merite, and
R Schreiber, and
P Landais, and
G Grau, and
J Bluestone, and
J F Bach, and
L Chatenoud
January 1991,
Comptes rendus des seances de la Societe de biologie et de ses filiales,
C Ferran, and
M Dy, and
K Sheehan, and
S Merite, and
R Schreiber, and
P Landais, and
G Grau, and
J Bluestone, and
J F Bach, and
L Chatenoud
February 1991,
Transplantation proceedings,
C Ferran, and
M Dy, and
K Sheehan, and
S Merite, and
R Schreiber, and
P Landais, and
G Grau, and
J Bluestone, and
J F Bach, and
L Chatenoud
October 1990,
Journal of immunology (Baltimore, Md. : 1950),
C Ferran, and
M Dy, and
K Sheehan, and
S Merite, and
R Schreiber, and
P Landais, and
G Grau, and
J Bluestone, and
J F Bach, and
L Chatenoud
October 1998,
Lancet (London, England),
C Ferran, and
M Dy, and
K Sheehan, and
S Merite, and
R Schreiber, and
P Landais, and
G Grau, and
J Bluestone, and
J F Bach, and
L Chatenoud
September 1993,
European journal of immunology,
C Ferran, and
M Dy, and
K Sheehan, and
S Merite, and
R Schreiber, and
P Landais, and
G Grau, and
J Bluestone, and
J F Bach, and
L Chatenoud
May 1994,
The Journal of clinical investigation,
C Ferran, and
M Dy, and
K Sheehan, and
S Merite, and
R Schreiber, and
P Landais, and
G Grau, and
J Bluestone, and
J F Bach, and
L Chatenoud
November 2015,
Oncology reports,
C Ferran, and
M Dy, and
K Sheehan, and
S Merite, and
R Schreiber, and
P Landais, and
G Grau, and
J Bluestone, and
J F Bach, and
L Chatenoud
October 2012,
Journal of immunological methods,
